Endonovo Therapeutics, Inc. announced that it has appointed Dr. Leonard Makowka, M.D., Ph.D., to serve as the company's Chief Medical Officer. Dr. Makowka was formerly the Chairman of the Department of Surgery and Director of Transplantation Services at Cedars Sinai Medical Center in Los Angeles, CA, and served as Professor of Surgery at the UCLA School of Medicine.

The company announced that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells. Endonovo's "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner than is possible with autologous and allogeneic stem cell therapies. There are currently more than 300 mesenchymal stem cell clinical trials underway to treat a wide range of pathological conditions listed on the ClinicalTrials.gov database. These clinical trials are still based on the transplantation of mesenchymal stem cells. Endonovo is developing therapies that may mitigate many of the current drawbacks of cell-based therapies, such as the low survival and engraftment rate of transplanted stem cells, the risk of occlusion in microvasculature, and unregulated growth, such as hyper-innervation or ossification and/or calcification in the body.